Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Geovax Labs

SIGA Technologies

The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to spread across countries in Africa and possibly outside the continent.

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

On Tuesday, Emergent BioSolutions Inc. EBS reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million.

Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks

Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript

GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2024.

Emergent BioSolutions Reports Second Quarter 2024 Financial Results

Meta Data Ltd

CommScope Hld

Hawaiian Electric Industries

Humacyte

Q32 Bio Inc

Cassava Sciences Inc

Serve Robotics Inc

The United States' macroeconomic environment was favorable to large-cap companies and unfriendly to small-caps through the first half of 2024. That changed in July.

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

Philadelphia, PA, July 31, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE: EBS) for an up-front payment of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon first achievement of a milestone relating to sourcing of certain components of RSDL®. As part of the transaction, SERB will also acquire and maintain the operation of the leased manufacturing facility in Hattiesburg, Mississippi and several employees who support the site and RSDL® product will join SERB.

SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million

GAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a global pharmaceutical company, for a purchase price of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon achievement of a milestone related to the sourcing of a certain component of RSDL®. The transaction has signed and closed simultaneously.

Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million

GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opioid emergency awareness public education campaign to prepare people across the country to help save a life with the ‘Lay, Spray, Stay' method. Sponsored by Emergent and created in partnership with SAFE Project, a national nonprofit combating substance use, overdoses and addiction, the campaign stars Pro Football Hall of Famer, Emmitt Smith, in a series of public awareness video and radio segments. The effort supports Emergent's national Ready to Rescue initiative, which breaks down the stigma associated with accidental opioid poisonings and informs Americans on the availability and use of NARCAN® Nasal Spray to help save a life.

Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay' Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith

GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance.

Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024

Ford Motor Company

Twenty-First Century Fox

Iron Mountain

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Watch These 4 Overbought Stocks As Market Rotation Continues

GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company's overall debt. This disciplined approach has enhanced Emergent's financial position, as well as enabling a customer focused, leaner and more flexible organization, and enriching its opportunities to pursue strategic initiatives.

Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan

Johnson & Johnson

Emergent BioSolutions said on Monday Johnson & Johnson has agreed to pay $50 million to settle claims related to a terminated manufacturing deal for the latter's COVID-19 vaccine.

Emergent, J&J settle COVID vaccine supply deal dispute

Nvidia Corp NVDA is trading lower Tuesday amid reports that the company faces antitrust charges from French regulators.

Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism.

Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent's Contract Development and Manufacturing Organization (CDMO), has clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. Alongside the facility, approximately 350 current Emergent employees are expected to join Bora as part of the transaction.

Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million

GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is highlighting its ongoing efforts to combat the opioid epidemic in the U.S., including topline results from its new general population awareness survey on consumers' understanding of opioid-related accidental overdose and fentanyl. The results show that there is a high level of awareness that fentanyl is an opioid, and that naloxone can reverse opioid overdoses, including those caused by fentanyl.1 It also found that there are still gaps in certain age groups and populations in understanding the role of naloxone in reversing opioid overdoses related to fentanyl.1

Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day

Advanced Micro Devices

Amazon

Alphabet

Microsoft

Impinj

Tencent Holdings Limited

The stock market continues to prove its resilience despite concerns over persistent inflation. A lot of that resilience is attributable to strong earnings reports overall.

7 Stocks to Buy Immediately Following Strong Earnings

DraftKings

Philip Morris

Quite often we read about societal pressures that have driven the increased use of everything from narcotics to gambling to even the reemergence of nicotine and tobacco. Unfortunately, with many of the economic difficulties of the 21st century, young people, now more than ever, rely on substances and thrills to get through the day.

Vice Stock Vanguards: 3 Sin Stocks Delivering Heavenly Returns

GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 23, 2024 at 9:00 am eastern time.

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

Emergent BioSolutions (NYSE: EBS ) layoffs are in the news as the life sciences company prepares to cut jobs and close down certain facilities. According to a release from Emergent BioSolutions, these layoffs will affect 300 of its employees.

Emergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job Cuts

Emergent BioSolutions (NYSE: EBS ) stock is taking off on Thursday after surprising investors with strong Q1 2024 earnings results. The life sciences company reported adjusted earnings per share of 59 cents for the quarter.

Why Is Emergent BioSolutions (EBS) Stock Up 57% Today?

Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2024 Earnings Call Transcript May 1, 2024 5:00 PM ET Company Participants Joe Papa - President and CEO Rich Lindahl - EVP and CFO Paul Williams - SVP, Products Business Operator Good afternoon, everyone. I'm the operator for today's call.

Emergent BioSolutions Inc. (EBS) Q1 2024 Earnings Call Transcript

Emergent BioSolutions is closing several manufacturing facilities and cutting hundreds of jobs as part of a restructuring as the company narrows its focus on products, including Narcan nasal spray.

Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024.

News for Emergent BioSolutions Stock (EBS)